“We are honored to have these eminent scientists and opinion leaders serving our Scientific Advisory Board,” said Dr. Katherine Cohen, Chief Executive Officer of Hookipa Biotech. “They will provide invaluable insight and guidance to advance our novel Vaxwave® technology platform for generating a wave of new vaccines.”
“I am happy to chair the Scientific Advisory Board of Hookipa”, said Dr. Paul-Henri Lambert. “Hookipa holds a promising vaccine technology platform for addressing the need of CD8+ T-cell and neutralizing antibody immune responses. The seasoned industrial team at Hookipa is making rapid progress towards the development of new generation vaccines.”
“I am very pleased to support Hookipa to develop a very innovative class of vaccine products which has the potential to meet the current medical challenges,” commented Dr. Stanley Plotkin.
Scientific Advisory Board:
Emeritus Prof. Dr. Paul-Henri Lambert (PhD)
Dr. Paul-Henri Lambert led the Immunology Research and Training Program of the WHO, and as professor in the Department of Pathology, University of Geneva, supervised the associated research laboratories at the Universities of Geneva and Lausanne (1975-1987).
In 1987, he was appointed Chief of Microbiology and Immunology at WHO; since 1994, he was Chief of Vaccine Research and Development for the WHO Global Program for Vaccines and Immunizations. He is directly associated with the Center of Vaccinology, at the University of Geneva.
Dr. Paul-Henri Lambert is now also Director of the International Advanced Course of Vaccinology organized by the Fondation Mérieux and University of Geneva, a member of several international scientific boards, and is author or co-author of over 400 publications.
Emeritus Prof. Dr. Stanley Plotkin ( MD)
Dr. Stanley A. Plotkin is Emeritus Professor at the University of Pennsylvania and Adjunct Professor at the Johns Hopkins University. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania, Professor of Virology at the Wistar Institute, and at the same time Director of Infectious Diseases and Senior Physician at the Children’s Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine company Pasteur-Mérieux-Connaught (now known as Sanofi Pasteur), based at Marnes-la-Coquette, outside Paris, where he was Medical and Scientific Director for seven years. Currently, Dr. Plotkin is consultant to vaccine manufacturers, biotechnology companies, and non-profit research organizations as principal of Vaxconsult, LLC.
Dr. Plotkin attended New York University, where he received a B.A. degree, and the State University of New York Medical School in Brooklyn, where he received an MD degree in 1956. His subsequent career included internship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Children’s Hospital of Philadelphia and the Hospital for Sick Children in London, and three years with the Epidemic Intelligence Service of the Centers for Disease Control of the US Public Health Service.
His bibliography includes more than 700 articles; he has edited several books including the standard textbook on Vaccines, now in its 6th edition. He developed the rubella vaccine now in standard use throughout the world, is co-developer of the newly licensed pentavalent rotavirus vaccine, and has worked extensively on the development and application of other vaccines including anthrax, oral polio, rabies, varicella, and cytomegalovirus.
Prof. Dr. Michael Mach (PhD)
Dr. Mach is Professor for Virology at the Institute of Virology, University Erlangen-Nürnberg. His research interest centers on Herpes virus envelope glycoproteins with emphasis on viral morphogenesis and the humoral immune response. Dr. Mach has studied pharmacy and received his PhD from the University of Erlangen-Nürnberg, Germany. Following a post-doctoral stay at the University of Washington, Seattle, USA, Dr. Mach returned to the University of Erlangen-Nürnberg as Professor for Virology in 1993.
Dr. Arnaud Marchant (MD, PhD)
Arnaud Marchant, MD, PhD, Université Libre de Bruxelles, is conducting research in the field of infectious disease and vaccine immunology. He developed a research program in early-life immunology during his post-doctoral stay at the Medical Research Council Laboratories, The Gambia, and Weatherall Institute for Molecular Medicine, Oxford. He is currently a senior research associate at the Fonds de la Recherche Scientifique, Belgium, and heads a research group at the Institute for Medical Immunology of the Université Libre de Bruxelles. Dr. Marchant is also Scientific Director of ImmuneHealth, a non-profit research center specialized in clinical immunology.
Prof. Dr. Franz Heinz (PhD)
Dr. Franz X. Heinz is Full Professor of Virology at the Medical University of Vienna and since 2004 Director of the Department of Virology. His major research achievements and interests are in the area of flaviviruses, including vaccine development, molecular antigenic structure and immune responses, mechanisms of virus entry and viral epidemiology. From 1987 to 1993 Dr. Heinz was a member of the WHO steering committee for the development of dengue and Japanese encephalitis vaccines and from 2006 to 2011 he served on the Scientific Advisory Board of the vaccine manufacturer Intercell. Currently Franz X. Heinz is a member of the National Academy of Germany ‘Leopoldina’ and a core member of the European Academy of Microbiology, as well as a member of the Scientific Advisory Boards of the Robert-Koch Institute in Berlin and the Bernhard Nocht Institute for Tropical Medicine in Hamburg.
About Hookipa Biotech
Hookipa Biotech, founded in Vienna, Austria in summer 2011, develops a new class of innovative prophylactic and therapeutic vaccines based on its proprietary Vaxwave® technology.
The Vaxwave® technology is a novel vaccine platform using a replication-defective viral vector for the prevention and treatment of multiple infectious diseases and cancer. The platform is one of the most promising new technologies for next generation vaccines due to its ability to stimulate both potent B-cell and CD8+ T-cell immune responses. Vaxwave® has been validated in various disease models. Unlike other vectors, Vaxwave® vaccines can be administered repeatedly to boost the immune system.
In October 2011, Hookipa raised €7 million from internationally renowned venture capital investors, Sofinnova Partners and Forbion Capital Partners. The company currently focuses on the development of its lead vaccine candidate HB101 and plans to further industrialize the Vaxwave® technology and build a robust product pipeline. Hookipa has recently moved into its state-of-the-art BSL2 facility at the Campus Vienna Biocenter.